News | Ventricular Assist Devices (VAD) | October 06, 2015

Aortix Heart Failure Pump Chosen for TCT “Shark Tank” Competition

Panel of judges will vote on the best technological concepts of the year
 

Aortix device, TCT, Interventional Innovation Shark Tank Competition, catheter-based circulatory heart pump

Image courtesy of Procyrion

October 6, 2015 — The novel Aortix device has earned a spot among the diagnostic and therapeutic modalities accepted for presentation in the Interventional Innovation “Shark Tank” Competition at the Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium. The event will be held Tuesday, Oct. 13, in San Francisco, California.

Developed by Procyrion Inc., Aortix is designed to be the first catheter-based circulatory heart pump specifically for New York Heart Association (NYHA) Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions. The small but powerful micro-pump is deployed downstream of the carotid arteries, which has the potential to eliminate major risks associated with thrombotic strokes, and the device is suitable for ambulatory use.

Duke University cardiologist and Procyrion Scientific Advisory Board member Manesh Patel, M.D., will have eight minutes to present the novel booster pump before a unique group of reviewers who will select the best technological concepts of the year. The top three finalists will be selected to answer additional questions from the judges and the winner and first-runner up will be announced Thursday, Oct. 15.

The Aortix device is not approved for use or sale.

For more information: www.procyrion.com

Related Content

Cardiothoracic surgeons with UofL Health – Jewish Hospital and the University of Louisville performed the world’s first Carmat Aeson bioprosthetic total artificial heart implantation in a female patient on Sept. 14, 2021. The device was small enough to fit into the woman's smaller chest cavity. The device is being tested as a bridge to heart transplant rather than use of a LVAD. Photo by UofL Health.

Cardiothoracic surgeons with UofL Health – Jewish Hospital and the University of Louisville performed the world’s first Carmat Aeson bioprosthetic total artificial heart implantation in a female patient on Sept. 14, 2021. The device was small enough to fit into the woman's smaller chest cavity. The device is being tested as a bridge to heart transplant rather than use of a LVAD. Photo by UofL Health.

News | Heart Failure | September 22, 2021
September 22, 2021 — A cardiothoracic surgical team with University of Louisville Health – Jewish Hospital has perfor
NIVAHF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients

NIVAHF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients.

News | Heart Failure | June 15, 2021
June 15, 2021 — VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital
The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.

The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.

News | Heart Failure | June 07, 2021
June 7, 2021 – Cardiologists at Hen...
RAFT-AF study showed type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart  heart and atrial fibrillation. #ACC21 #ACC2021

RAFT-AF study showed the type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart heart and atrial fibrillation. Getty Images

News | Heart Failure | May 19, 2021
May 19, 2021 — Among patients with both ...
The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF

The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients.

News | Heart Failure | May 18, 2021
May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a gre
The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor. #ACC21 #ACC2021

The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor.

News | Heart Failure | May 15, 2021
May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the ra
Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease or cardiovascular risk factors, a new Mount Sinai study shows. 

Getty Images

News | Heart Failure | May 11, 2021
May 11, 2021 — Patients hospitalized with COVID-1...
Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology

Image courtesy of the American Journal of Physiology.

News | Heart Failure | April 26, 2021
April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States.
PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

News | Heart Failure | March 24, 2021
March 24, 2021 — Endotronix Inc., a digital health and medical technology company working on advancements in treating